TL;DR: MOTS-c (Mitochondrial ORF of the 12S rRNA-c) is a 16-amino-acid peptide encoded within the mitochondrial genome, specifically a short open reading frame (sORF) inside the 12S rRNA gene. First described by Lee et al. in Cell Metabolism (2015), it is classified as a mitochondrial-derived peptide (MDP). Preclinical research documents AMPK pathway activation, improved insulin sensitivity in skeletal muscle models, nuclear translocation under metabolic stress, and exercise-mimetic signaling. The research base is predominantly rodent and cell culture. MOTS-c is not FDA approved, has no authorized human use, and no large human RCTs have been completed as of 2026.
Research-Use Disclaimer: This article is for educational and research reference purposes only. MOTS-c is a research compound, not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research unless explicitly noted. For adults 21+ with a research interest only.
What Is MOTS-c? Definition, Origin, and Discovery
MOTS-c, short for Mitochondrial ORF of the 12S rRNA-c, is a 16-amino-acid peptide encoded within a short open reading frame (sORF) embedded in the mitochondrial 12S ribosomal RNA gene. It was first identified and characterized by Lee and colleagues at the University of Southern California’s Leonard Davis School of Gerontology, with the seminal paper published in Cell Metabolism in March 2015 (PMID: 25738459).
Prior to the identification of MOTS-c, it was thought that the mitochondrial genome (mtDNA) encoded only 37 genes: 22 tRNAs, 2 rRNAs, and 13 mRNAs. The discovery of humanin, a peptide encoded in the 16S rRNA region of the mtDNA, suggested the mitochondrial genome might contain additional functional sORFs. Lee et al. (2016) in Free Radical Biology and Medicine described MOTS-c as evidence of a larger mitochondrial genetic repertoire, expanding the known coding capacity of the organelle that was once considered metabolically passive at the genetic level.
MOTS-c is co-localized with mitochondria across various tissues and is detectable in plasma. Zheng et al. (2023) in Frontiers in Endocrinology reviewed evidence indicating that circulating MOTS-c levels decline with age, a finding that has attracted interest in the context of aging biology research.
What Mechanisms Has MOTS-c Research Documented?
MOTS-c does not appear to act through a single receptor. Peer-reviewed research has described several intersecting pathways through which it exerts documented effects in preclinical models. The four most consistently reported mechanisms are detailed below.
1. AMPK Activation via the Folate-AICAR Pathway
The foundational 2015 Cell Metabolism study by Lee et al. described MOTS-c’s primary cellular mechanism: inhibition of the folate cycle and its tethered de novo purine biosynthesis pathway. This inhibition elevates cellular AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a known AMPK activator. The result is activation of AMPK (AMP-activated protein kinase), the central energy-sensing enzyme that regulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Lee et al. found that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity, through this mechanism.
A 2023 review by Wan et al. in Journal of Translational Medicine characterized this as the “Folate-AICAR-AMPK pathway” and reviewed evidence that it underlies MOTS-c’s documented influences on energy metabolism, insulin resistance, and stress homeostasis.
2. Nuclear Translocation Under Metabolic Stress
A key mechanistic finding published in Cell Metabolism in 2018 by Kim, Son, Benayoun, and Lee demonstrated that MOTS-c is not confined to the mitochondria. Under conditions of metabolic stress (including glucose restriction), MOTS-c translocates from the mitochondria to the nucleus, where it regulates nuclear gene expression in an AMPK-dependent manner. In the nucleus, MOTS-c was found to regulate genes containing antioxidant response elements (ARE) and to interact with the stress-responsive transcription factor NRF2 (nuclear factor erythroid 2-related factor 2). This represented what the authors described as evidence that the mitochondrial and nuclear genomes “co-evolved to independently encode for factors to cross-regulate each other”, a concept termed mitonuclear communication.
3. Insulin Sensitivity and Metabolic Regulation in Skeletal Muscle
The primary target organ identified in MOTS-c research is skeletal muscle. The 2015 Lee et al. study found that MOTS-c’s primary cellular activity was concentrated in muscle tissue, with enhanced glucose uptake documented in skeletal muscle cell models. Yin et al. (2021) in Pharmacological Research extended these findings to a gestational diabetes mouse model, finding that MOTS-c administration significantly alleviated hyperglycemia, improved insulin sensitivity and glucose tolerance, and activated insulin signaling in skeletal muscle of the GDM mouse model, alongside apparent protection of pancreatic beta-cells from injury.
Mohtashami et al. (2022) in International Journal of Molecular Sciences reviewed MOTS-c’s role across age-related diseases, characterizing aging as associated with gradual loss of mitochondrial metabolic balance and noting that MOTS-c treatment in animal models has been studied as a potential countermeasure to age-related declines in muscle homeostasis and metabolic function.
4. Exercise-Mimetic Signaling
MOTS-c has been described in the literature as an “exercise-mimetic” signal, a compound whose documented biological actions parallel some of the metabolic adaptations produced by physical exercise. Lee, Kim, and Cohen (2016) described MOTS-c as implicating “the regulation of obesity, diabetes, exercise, and longevity, representing an entirely novel mitochondrial signaling mechanism.” The Wan et al. (2023) review in Journal of Translational Medicine further noted that MOTS-c expression is significantly upregulated in response to exercise and translocated to the nucleus during both exercise and metabolic stress conditions, suggesting a role in mediating some of the beneficial metabolic adaptations associated with physical activity, in preclinical contexts.
5. Cardiovascular and Anti-Inflammatory Research Contexts
More recent preclinical studies have examined MOTS-c in cardiovascular models. Zhong et al. (2022) in the Journal of Cellular and Molecular Medicine reported that MOTS-c peptide attenuated pressure overload-induced cardiac dysfunction and remodelling in a mouse model of heart failure, with AMPK pathway activation, reduced inflammatory response, and upregulated antioxidant capacity documented as associated mechanisms. Lu et al. (2023) in the European Journal of Pharmacology found decreased circulating MOTS-c levels in patients undergoing off-pump coronary artery bypass surgery who developed acute lung injury, and in animal models, MOTS-c suppressed ferroptosis (an iron-dependent form of cell death) via a PPARĪ³ signaling pathway. All findings are from preclinical or observational contexts.
What Is MOTS-c’s Evidence Tier? An Honest Assessment
Accurately representing the state of MOTS-c evidence is essential for anyone discussing this compound in a research context. The following table summarizes the landscape as of 2026:
| Evidence Level | Status for MOTS-c (as of 2026) |
|---|---|
| Human randomized controlled trials | Not available; no large interventional human RCTs published |
| Human observational data | Limited, circulating MOTS-c levels measured in aging and surgical patient populations |
| Peer-reviewed animal model studies | Present, multiple rodent studies (obesity, diabetes, heart failure, gestational diabetes models) |
| In vitro / cell culture evidence | Present, AMPK activation, nuclear translocation, ARE regulation documented in cell lines |
| FDA approval status | Not approved for any human use |
| Research compound classification | Preclinical / investigational |
The honest limitation to state clearly: MOTS-c research is an active and growing field, but it remains predominantly at the preclinical stage. Rodent metabolic models and cell culture findings do not guarantee translation to human physiology. The molecular mechanisms, particularly AMPK activation and nuclear translocation, are well-characterized at a mechanistic level, but efficacy and safety in humans has not been established through controlled clinical trials. The exercise-mimetic framing, while compelling as a research hypothesis, is based on mechanistic parallels and animal data rather than human interventional evidence.
What Is MOTS-c’s Regulatory Status?
FDA (United States)
MOTS-c is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no approved indication, no authorized dosing protocol for human use, and is classified as a research compound. Researchers should consult current FDA guidance and applicable regulations directly.
Research Classification
MOTS-c occupies the same general regulatory category as other mitochondrial-derived peptides: it is an investigational compound studied in preclinical models, with no pathway to human therapeutic use that has been authorized by any major regulatory body as of 2026. Unlike some research peptides that have entered Phase I/II clinical trials, MOTS-c has not advanced to registered human interventional trials.
Frequently Asked Questions About MOTS-c
What is MOTS-c?
MOTS-c (Mitochondrial ORF of the 12S rRNA-c) is a 16-amino-acid peptide encoded within a short open reading frame (sORF) in the mitochondrial 12S rRNA gene. It was first described by Lee et al. in Cell Metabolism (2015) and is classified as a mitochondrial-derived peptide (MDP), the second MDP identified after humanin. Its primary documented target organ in preclinical research is skeletal muscle.
Is MOTS-c FDA approved?
No. MOTS-c is not approved by the FDA for any therapeutic use in humans. It is a research compound studied predominantly in preclinical rodent and cell culture models. There is no authorized human dosing protocol, no approved clinical indication, and it is not legally available as a drug or dietary supplement in the United States.
What does MOTS-c do in research models?
In preclinical research, MOTS-c has been documented to activate AMPK via inhibition of the folate cycle and de novo purine biosynthesis; improve insulin sensitivity in skeletal muscle models; translocate to the nucleus under metabolic stress to regulate genes with antioxidant response elements; and reduce markers of obesity and insulin resistance in high-fat-diet mouse models. These findings originate from rodent and cell culture research.
What is MOTS-c’s evidence tier?
MOTS-c is a predominantly preclinical compound, multiple peer-reviewed animal and cell-culture studies have been published, but large human randomized controlled trials have not been conducted as of 2026. Plasma MOTS-c levels have been measured in humans in observational contexts (e.g., declining with age, reduced in surgical patients with lung injury), but these do not constitute interventional clinical evidence of efficacy or safety.
Research use only. Not intended for human use. Not FDA approved. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources on PubMed and publisher DOIs, read them in full. Must be 21+.